Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Wave Life Sciences (WVE) over the last 11 years, with Q3 2025 value amounting to $32.7 million.

  • Wave Life Sciences' Cash from Financing Activities fell 8395.45% to $32.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $83.5 million, marking a year-over-year decrease of 7330.5%. This contributed to the annual value of $253.9 million for FY2024, which is 9156.59% up from last year.
  • According to the latest figures from Q3 2025, Wave Life Sciences' Cash from Financing Activities is $32.7 million, which was down 8395.45% from $11.7 million recorded in Q2 2025.
  • In the past 5 years, Wave Life Sciences' Cash from Financing Activities registered a high of $203.7 million during Q3 2024, and its lowest value of $17000.0 during Q3 2022.
  • Its 5-year average for Cash from Financing Activities is $29.4 million, with a median of $8.6 million in 2021.
  • As far as peak fluctuations go, Wave Life Sciences' Cash from Financing Activities soared by 17775789.47% in 2021, and later tumbled by 9983.72% in 2022.
  • Quarter analysis of 5 years shows Wave Life Sciences' Cash from Financing Activities stood at $33.8 million in 2021, then tumbled by 99.84% to $55000.0 in 2022, then surged by 170740.0% to $94.0 million in 2023, then tumbled by 62.77% to $35.0 million in 2024, then decreased by 6.54% to $32.7 million in 2025.
  • Its last three reported values are $32.7 million in Q3 2025, $11.7 million for Q2 2025, and $4.2 million during Q1 2025.